Invivyd IVVD 深 滬
已收盤 07-31 16:00:00 美东时间
0.535
-0.047
-8.01%
華盛通- 最 高0.5981
- 今 開0.5816
- 成交量 230.38万股
- 最 低 0.5277
- 昨 收 0.5816
- 總市值 1.58亿
- 52周最高 3.0699
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 0.483
- 委 比 -58.76%
- 總股本 2.95亿
- 歷史最高 78.82
- 量 比 0.69
- 振 幅 12.10%
- 歷史最低 0.3546
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 制药企业CRNX股价狂飙近99%！获福泰制药百亿美元高溢价收购；罕见病药物研究公司AGIO涨18%
制药企业CRNX股价狂飙近99%！获福泰制药百亿美元高溢价收购；罕见病药物研究公司AGIO涨18%，核心产品新药申请获FDA受理；基因治疗药物研发企业NGNE涨13%，公司成功完成新一轮融资>>
07-08 19:19
Invivyd gets notice of Pemgarda EUA termination
Invivyd (IVVD) received a notice from the U.S. Food and Drug Administration terminating the emergency use authorization for PEMGARDA, its monoclonal antibody for COVID-19 prevention, effective June 29...
07-06 19:36
Invivyd Plans Post-EUA Pathway for PEMGARDA Antibody
Invivyd ( ($IVVD) ) has issued an announcement. On July 6, 2026, Invivyd announ...
07-06 19:28
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
U.S. HHS announced the termination of the COVID-19 EUA declaration effective June 29, 2027, leading to the end of PEMGARDA's EUA on the same date after a 12-month transition period. Invivyd is engaging with the FDA to explore next steps, aiming to secure permanent approval for PEMGARDA, a monoclonal antibody providing critical non-vaccine COVID protection for vulnerable populations. Despite the EUA termination, Invivyd believes PEMGARDA's clinica...
07-06 11:01
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. granted 14 newly hired non-executive employees stock options for 493,000 shares on July 1, 2026, under the 2026 Inducement Plan. The options have an exercise price of $0.8544, vest over four years, and expire in 10 years. The company focuses on developing antibodies to combat viral diseases like SARS-CoV-2.
07-02 11:01
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
NovaBridge Biosciences announced the appointment of Dr. Srishti Gupta as CEO, effective July 1, 2026, succeeding Dr. Xi-Yong Fu, who will transition to an advisory role. Dr. Gupta, with over two decades of leadership in biopharmaceuticals and global health, aims to advance NovaBridge's innovative medicines, including givastomig and VIS-101, toward registration and establish strategic partnerships. NovaBridge focuses on addressing significant unme...
06-29 11:00
Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026
Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis and COVID vaccine. LIBERTY is part of Invivyd's broader REVOLUTION clinical program, including DECLARATION, designed to generate medical practice-changing data to...
06-16 19:14
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Invivyd Dosed The First Participants In LIBERTY Phase 3 Trial Of VYD2311 Alone, And VYD2311 Co-administered With A Covid-19 Vaccine In Healthy Adults; Topline Data Is Expected In Q3 2026, To Accompany Anticipated Data From Pivotal DECLARATION Study
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19
06-09 19:06
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
Invivyd, Inc. has initiated the LIBERTY Phase 3 clinical trial to evaluate the safety, tolerability, and immunology of VYD2311, a monoclonal antibody (mAb) candidate, compared to an mRNA COVID-19 vaccine, as well as their co-administration in healthy adults. The trial aims to provide data on the comparative safety profiles and potential benefits of mAb-mediated prophylaxis over traditional vaccines. Topline results are expected in Q3 2026, alongs...
06-09 11:01
